

LITERATURA

- Coley WB. Contribution to the Knowledge of Sarcoma. *Ann Surg* 1891; 14: 199–220.
- Graham JB, Graham RM. The effect of vaccine on cancer patients. *Surg Gynecol Obstet* 1959; 109: 131–138.
- Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. *N Engl J Med* 1985; 313: 1485–1492.
- Decker WK, da Silva RF, Sanabria MH, et al. Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models. *Front Immunol* 2017; 8: 829.
- Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. *N Engl J Med* 1988; 319: 1676–1680.
- Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. *Proc Natl Acad Sci USA* 1989; 86: 10024–10028.
- Romeo C, Seed B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. *Cell* 1991; 64: 1037–1046.
- Roberts MR, Qin L, Zhang D, et al. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. *Blood* 1994; 84: 2878–2889.
- Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. *Nat Med* 2003; 9: 279–286.
- Firor AE, Jares A, Ma Y. From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy. *Exp Biol Med (Maywood)* 2015; 240: 1087–1098.
- Filley AC, Henriquez M, Dey M. CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors. *Front Oncol* 2018; 8: 453.
- Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. *N Engl J Med* 2018; 378: 439–448.
- Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *N Engl J Med* 2017; 377: 2531–2544.
- Robillard N, Wuilleme S, Moreau P, et al. Immunophenotype of normal and myelomatous plasma-cell subsets. *Front Immunol* 2014; 5: 137.
- Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T-cells for sustained remissions in leukemia. *N Engl J Med* 2014; 371: 1507–1517.
- Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med* 2019; 380: 45–56.
- Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. *Lancet* 2015; 385: 517–528.
- Monjezi R, Miskey C, Gogishvili T, et al. Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors. *Leukemia* 2017; 31: 186–194.
- Zhao Y, Moon E, Carpenito C, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. *Cancer Res* 2010; 70: 9053–9061.
- Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. *Blood Rev* 2019; 34: 45–55.
- Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. *Biol Blood Marrow Transplant* 2019; 25: 625–638.
- Zang YW, Gu XD, Xiang JB, et al. Clinical application of adoptive T cell therapy in solid tumors. *Med Sci Monit* 2014; 20: 953–959.
- Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. *Immunol Rev* 2014; 257: 83–90.
- Tokarew N, Ogonek J, Endres S, et al. Teaching an old dog new tricks: next-generation CAR T cells. *Br J Cancer* 2019; 120: 26–37.
- Bagley SJ, O'Rourke DM. Clinical investigation of CAR T cells for solid tumors: lessons learned and future directions. *Pharmacol Ther* 2019; 16: 107419.
- Majzner R, Mackall CL. Tumor Antigen Escape from CAR T-cell Therapy. *Cancer Discov* 2018; 8: 1219–1226.
- Hegde M, Mukherjee M, Grada Z, et al. Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. *J Clin Invest* 2016; 126: 3036–3052.
- Huang L, Wang N, Li C, et al. Sequential infusion of anti-CD22 and Anti-CD19 chimeric antigen receptor T cells for adult patients with refractory/relapsed B-cell acute lymphoblastic leukemia. *Blood* 2017; 130: 846.

Další literatura u autora
a na www.casopisvnitrnilekarstvi.cz

Vzdělávejte se on-line a získajte kredity

SOLEN MEDICAL EDUCATION

ON-LINE KURZ **Závratě**



Dovolujeme si Vás pozvat k on-line kurzu tematicky zaměřenému na závratě. Závratě a poruchy rovnováhy patří k nejčastějším příznakům vůbec a s věkem frekvence závrativých potíží narůstá. Proto je tato problematika velmi aktuální nejen pro neurology, ale také pro všeobecné praktické lékaře či internisty.

Kurz je ohodnocen 2 kredity v rámci celoživotního postgraduálního vzdělávání dle Stavovského předpisu ČLK č. 16. Registrace je zdarma. Po zhlédnutí všech edukačních zdrojů a úspěšném absolvování závěrečného testu alespoň na 80 % vám bude certifikát zaslán na e-mail, pomocí kterého jste se registrovali.

PŘEDNÁŠKY

- Závrativé stavy**
doc. MUDr. Dr. Med. Aleš Hahn, CSc.,
ORL klinika FNKV a 3. LF UK, Praha
- Diferenciální diagnóza vertiga**
doc. MUDr. Jaroslav Jeřábek, CSc.,
Neuro-otologické centrum
1. a 2. LF UK v Praze FN Motol, Praha

TERMÍN: říjen 2020 – září 2021

dostupný na online.solen.cz

ODBORNÝ GARANT: doc. MUDr. Jaroslav Jeřábek, CSc.
Neuro-otologické centrum 1. a 2. LF UK v Praze FN Motol, Praha

DĚLKA KURZU: 90 min.

POŘADATEL: SOLEN, s. r. o.

POČET KREDITŮ: 2

KONTAKTNÍ OSOBA:

Mgr. Kristýna Slouková
+420 773 779 632, sloukova@solen.cz
online.solen.cz

www.jaknavertigo.cz ↓



PARTNER
KURZU

Mylan

Better Health
for a Better World

MEDIÁLNÍ PARTNEŘI

